Solo educación · requiere revisión profesional
Retatrutide · Triple agonist in phase 3 trials
Not approved, not available — and heavily marketed anyway. Here is where it actually stands.
Revisado médicamente por Bernard Garcia, MD
Qué es
Retatrutide is an investigational peptide that activates three receptors: GLP-1, GIP and glucagon. It is in phase 3 clinical trials run by its manufacturer and is not approved anywhere. Phase 2 results published in 2023 showed large average weight reduction over 48 weeks, which is why it is widely discussed.
Anything sold online under this name is an unregulated copy of an unapproved investigational drug.
Cómo funciona
The glucagon-receptor component is intended to add energy-expenditure and liver-fat effects to the GLP-1/GIP appetite mechanisms. Phase 3 trials are measuring weight, cardiovascular outcomes and safety over longer periods; results and any approval decision are pending.
Estado de la investigación
| Área de investigación | Estado |
|---|---|
| Chronic weight management | Phase 3 trials ongoing · not approved |
| Type 2 diabetes | Phase 3 trials ongoing |
| Long-term safety | Not established |
| Regulatory status (US FDA) | Investigational · no approval |
El estado refleja únicamente el contexto de la investigación publicada y no constituye una afirmación de seguridad, eficacia o idoneidad para ninguna persona.
¿Es legal?
Retatrutide is an investigational drug with no approval in any country. It cannot be lawfully prescribed or compounded, and "research use only" products are not for human use. This is a general note, not legal advice.
Preguntas frecuentes
When will retatrutide be approved?
No date exists. Phase 3 results and regulatory review come first; this page will be updated when the status changes.
Can a provider prescribe it now?
No. It is investigational and not available outside clinical trials.
What about online sellers offering it?
Those products are unapproved, untested copies. They are the kind of product our safety page describes as a red flag.
Siguiente paso
Siguiente paso: una consulta confidencial de 3 minutos, revisada por un profesional con licencia. No se promete ni se da a entender ningún tratamiento.
Gratis · unos 10 minutos · revisado por un médico con licencia
Educación general · No es consejo médico · Se requiere aprobación profesional